Global Pericarditis Treatment Market Size study, By Disease Type (Acute Pericarditis Treatment, Chronic Pericarditis Treatment, Recurrent Pericarditis Treatment, Idiopathic Pericarditis Treatment), By Treatment Type (Pericarditis Therapeutics, Nonsteroi

Global Pericarditis Treatment Market Size study, By Disease Type (Acute Pericarditis Treatment, Chronic Pericarditis Treatment, Recurrent Pericarditis Treatment, Idiopathic Pericarditis Treatment), By Treatment Type (Pericarditis Therapeutics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Antibiotic/Antifungal Medication, Corticosteroids, Pericarditis Treatment through Surgery, Pericardiectomy, Pericardiocentesis, Pericardiotomy), By End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Academic & Research Institutes), and Regional Forecasts 2022-2028

Global Pericarditis Treatment Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Pericarditis is an inflammation of the pericardium. It can be defined as swelling and irritation of the thin, saclike tissue surrounding the heart named pericardium. Pericarditis generally occurs due to respiratory or digestive system infection. The most common symptom of acute pericarditis is a sharp, stabbing chest pain. The growing prevalence of cardiovascular diseases and increasing incidences of recurrent pericarditis as well as favorable initiatives from regulatory authorities are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates – during 2019, around 17.9 million people around the world succumbs to cardiovascular diseases (CVDs), witnessed for around 32% of all global deaths occurred in 2019. Moreover, as per American College of Epidemiology – in United States Recurrent Pericarditis (RP) population is estimated at 36,500 with 19,500 incident cases annually equating to 6.0/100,000 incidence and prevalence rate of 10.9/100,000 incidence. Furthermore, Recent treatment approvals from regulatory authorities would influence the growth of Pericarditis Treatment Market. For instance, in March 2021, US based Regeneron Pharmaceuticals, Inc. received FDA approval for its Arcalyst (rilonacept) injection to treat recurrent pericarditis in adults and children 12 years and older. Also, growing number of geriatric individuals coupled with surging healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, stringent rules and regulations from government authorities and high treatment cost impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Pericarditis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing development of pericarditis treatment solutions and presence of leading pharmaceuticals players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of healthcare sector and rising geriatric population in the region, would create lucrative growth prospects for the global Pericarditis Treatment Market across the Asia Pacific region.

Major market players included in this report are:
Pfizer Inc.
Bayer AG
PerkinElmer Inc.
ALLERGAN
Lincoln Pharmaceuticals Ltd.
Unicure India Pvt. Ltd.
Zydus Cadila Healthcare Ltd.
Aasraw Biochemical Technology Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Disease Type:
Acute Pericarditis Treatment
Chronic Pericarditis Treatment
Recurrent Pericarditis Treatment
Idiopathic Pericarditis Treatment
By Treatment Type:
Pericarditis Therapeutics
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Antibiotic/Antifungal Medication
Corticosteroids
Pericarditis Treatment through Surgery
Pericardiectomy
Pericardiocentesis
Pericardiotomy
By End Use:
Hospitals
Clinics
Ambulatory Surgical Centers
Academic & Research Institutes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pericarditis Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Pfizer Inc.
Bayer AG
PerkinElmer Inc.
ALLERGAN
Lincoln Pharmaceuticals Ltd.
Unicure India Pvt. Ltd.
Zydus Cadila Healthcare Ltd.
Aasraw Biochemical Technology Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.